Helix Biopharma announces addition of University of Arizona professor Kenneth Hatch as new medical advisor

    AURORA, ON, Oct. 11 /CNW/ - Helix BioPharma Corp. (TSX: HBP / Frankfurt:
WKN 918864) announced today the addition of Kenneth D. Hatch, M.D., as a new
medical advisor to the Company. Dr. Hatch will provide guidance to Helix on
its clinical-stage compound, Topical Interferon Alpha-2b, for the treatment of
conditions caused by HPV. Dr. Hatch is a professor of obstetrics and
gynecology at the University of Arizona.
    "Dr. Hatch complements our medical advisory team and brings additional
strength to Helix' expertise in the field of gynecology and pre-invasive
diseases of the cervix", said John Docherty, vice president, corporate
development at Helix. "We are very pleased to establish this relationship with
Dr. Hatch, and expect that he will be an invaluable asset to the Company as we
continue to move forward with the preparations for our planned IND/CTA filings
for Topical Interferon Alpha-2b".
    Previously, Dr. Hatch was president of the American Society of Colposcopy
and Cervical Pathology. Dr. Hatch has also presided as secretary-treasurer of
the International Federation of Colposcopy and Cervical Pathology, and as
president of the Society of Gynecologic Oncologists.

    About Helix BioPharma Corp.

    Helix BioPharma Corp. is a biopharmaceutical company specializing in the
field of cancer therapy. The Company is actively developing innovative
products for the prevention and treatment of cancer based on its proprietary
technologies. Helix's product development initiatives include its Topical
Interferon Alpha-2b, for the treatment of conditions caused by HPV, and its
novel L-DOS47 new drug product candidate for the treatment of lung
adenocarcinoma. Helix is listed on the Toronto Stock Exchange under the ticker
symbol "HBP".

    This News Release contains certain forward-looking statements and
information regarding Helix's product development initiatives, Topical
Interferon Alpha-2b and L-DOS47. Forward-looking statements and information
can be identified by the use of forward-looking terminology such as "expect",
"planned", "developing", and "initiatives". Helix's actual results could
differ materially from those anticipated in these forward-looking statements
and information as a result of numerous factors, including without limitation,
Helix's need for additional capital in the near term and in future, which may
not be available on acceptable terms or at all; uncertainty whether the
IND/CTA filings for Topical Interferon Alpha-2b will be filed as planned;
research and development risks; and uncertainty whether Topical Interferon
Alpha-2b, L-DOS47, or any other product will be developed and marketed
successfully as a drug or at all. See a description of other risks and
uncertainties affecting Helix and its business, as contained in Helix's latest
Annual Information Form and other filings with the Canadian Securities
Regulatory Authorities at www.sedar.com, any of which could cause actual
results to vary materially from current results or Helix's anticipated future
results. Forward-looking statements and information are based on the beliefs,
opinions and expectations of Helix's management at the time they are made, and
Helix does not assume any obligation, except as required by law, to update any
forward-looking statement or information should those beliefs, opinions or
expectations, or other circumstances change.

For further information:

For further information: Investor Relations: Christina Bessant, The
Equicom Group Inc., Tel: (416) 815-0700 ext. 269, (800) 385-5451, Fax: (416)
815-0080, Email: cbessant@equicomgroup.com; Media Relations: Benjamin
Carmichael, Russo Partners LLC, Tel: (212) 845-4242, Fax: (212) 845-4260,
Email: benjamin.carmichael@russopartnersllc.com, www.russopartnersllc.com

Organization Profile


More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890